Compare TRVI & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVI | SDGR |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2019 | 2020 |
| Metric | TRVI | SDGR |
|---|---|---|
| Price | $10.15 | $16.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $20.38 | ★ $24.90 |
| AVG Volume (30 Days) | ★ 1.3M | 903.8K |
| Earning Date | 03-17-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $256,951,000.00 |
| Revenue This Year | N/A | $23.69 |
| Revenue Next Year | N/A | $20.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.90 |
| 52 Week Low | $3.73 | $15.99 |
| 52 Week High | $14.39 | $28.47 |
| Indicator | TRVI | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 38.08 |
| Support Level | $10.17 | $16.07 |
| Resistance Level | $11.15 | $17.87 |
| Average True Range (ATR) | 0.73 | 0.77 |
| MACD | -0.13 | -0.20 |
| Stochastic Oscillator | 3.52 | 9.83 |
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.